rs138213197
|
|
|
0.800 |
GeneticVariation |
BEFREE |
While there was a trend toward an earlier age at diagnosis, overall the clinicopathologic features of PCa were not significantly different in G84E carriers and non-carriers.
|
29181843 |
2018 |
rs138213197
|
|
|
0.800 |
GeneticVariation |
BEFREE |
While the HOXB13 G84E mutation may be rare, there may be a future role in genetic testing for this mutation after further studies of clinical utility in assessing prostate cancer risk.
|
24310616 |
2014 |
rs138213197
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We performed a retrospective analysis of germline DNA samples from Ashkenazi Jewish men and a comparison group of non-Ashkenazi men treated for prostate cancer at our institution to determine the prevalence of HOXB13 G84E mutation in prostate cancer patients of Ashkenazi Jewish heritage, an ethnic group common to the New York City area.
|
23475555 |
2013 |
rs138213197
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We identified 101 heterozygous carriers of G84E who underwent radical prostatectomy for prostate cancer between 1985 and 2011 and matched these men by race, age and tumor grade to 99 HOXB13 wild-type controls.
|
28186998 |
2017 |
rs138213197
|
|
|
0.800 |
GeneticVariation |
BEFREE |
This study confirms the overall importance of the HOXB13 G84E mutation in prostate cancer susceptibility.
|
23292082 |
2013 |
rs138213197
|
|
|
0.800 |
GeneticVariation |
BEFREE |
These findings demonstrate that the HOXB13 G84E mutation is present in ~5 % of prostate cancer families, predominantly of European descent, and confirm its association with prostate cancer risk.
|
23064873 |
2013 |
rs138213197
|
|
|
0.800 |
GeneticVariation |
BEFREE |
There was a stronger association between the G84E variant and PC among men with no first-degree relative with PC (OR, 4.04; 95% CI, 1.12-14.51) compared to men with a family history of PC (OR, 1.49; 95% CI, 0.30-7.50; P = 0.36 for interaction).
|
23129385 |
2013 |
rs138213197
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Then, 25 studies including 51,390 cases and 93,867 controls were included, and there was significant association between HOXB13 p.Gly84Glu mutation and overall cancer risk (OR = 2.872, 95% CI = 2.121-3.888, P < 0.001), particularly in prostate cancer (OR = 3.248, 95% CI = 2.313-4.560, P < 0.001), while no association was found in breast (OR = 1.424, 95% CI = 0.776-2.613, P = 0.253) and colorectal cancers (OR = 2.070, 95% CI = 0.485-8.841, P = 0.326).
|
26517352 |
2015 |
rs138213197
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The recurrent p.Gly84Glu germline mutation (G84E) in HOXB13 is consistently associated with prostate cancer (PCa), although the mechanisms underlying such linkage remain elusive.
|
30560549 |
2019 |
rs138213197
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The HOXB13 G84E variant is associated with risk of prostate cancer (PCa), however the role this variant plays in P</span>Ca development is unknown.
|
29259341 |
2017 |
rs138213197
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The HOXB13 G84E mutation was identified in 0.49% of controls and in 2.51% of PCa cases.
|
26779768 |
2016 |
rs138213197
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The germline mutation G84E of HOXB13 is a rare but recurrent mutation associated with elevated risk of prostate cancer in men of European descent, with an effect size that is greater than observed for previously validated risk variants of genome wide association studies.
|
22714738 |
2012 |
rs138213197
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The clinical importance of HOXB13 G84E in PrCa management has not been established.
|
25595936 |
2015 |
rs138213197
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The absolute PCa risk by age 85 for a male HOXB13 G84E carrier varied from 60% for those with no PCa family history to 98% for those with two relatives diagnosed at young ages, compared with an average risk of 15% for noncarriers.
|
30527799 |
2019 |
rs138213197
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The age-specific risk of prostate cancer among G84E mutation carriers was higher than among non-carriers.
|
25629170 |
2015 |
rs138213197
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The G84E mutation predisposes to prostate cancer in Poland, but accounts for only a small proportion of cases.
|
23334858 |
2013 |
rs138213197
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The G84E variant was detected in 4 patients (prevalence 0.42%, 95% CI 0.12-1.08), of whom 3 had prostate cancer on biopsy.
|
23036981 |
2013 |
rs138213197
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The G84E mutation was more frequent among white case subjects than among white control subjects (10 of 1525 [0.7%] vs 2 of 1757 [0.1%], P = .01) and was associated with an increased risk of prostate cancer (unadjusted odds ratio = 5.8, 95% confidence interval = 1.3 to 26.5, P = .01).
|
22781434 |
2012 |
rs138213197
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The prostate cancer risk allele p.G84E was identified in 18 (0.56%) of 3,187 cases and 16 (0.70%) of 2,300 controls (OR = 0.81, 95% CI = 0.41-1.59, P = 0.54).
|
27424772 |
2016 |
rs138213197
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Testing for the G84E mutation in men with a positive family history may help distinguish those who merit more regular screening for prostate cancer.
|
23396964 |
2013 |
rs138213197
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Recent genetic epidemiologic studies identified a germline mutation in the homeobox transcription factor, HOXB13 G84E, which is associated with markedly increased risk for prostate cancer, particularly early-onset hereditary prostate cancer.
|
24722062 |
2014 |
rs138213197
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Our study has provided a population-based estimate of the average risk of prostate cancer for HOXB13 missense mutation G84E carriers that can be used to guide clinical practice and research.
|
23457453 |
2013 |
rs138213197
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Our study confirms the association between the HOXB13 G84E variant and prostate cancer and suggests a novel association between G84E and leukemia and a suggestive association with bladder cancer.
|
26108461 |
2015 |
rs138213197
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Our results indicated that significant increased PCa susceptibility was associated with rs138213197 compared with non-carriers (OR = 3.38, 95% CI: 2.45-4.66).
|
27626483 |
2016 |
rs138213197
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Interplay of <i>HOXB13</i> (G84E) and <i>CIP2A</i> (R229Q) variants results in highest observed inherited prostate cancer risk (OR, 21.1; <i>P</i> = 0.000024).
|
30181389 |
2018 |